http://escholarship.lib.okayama-u.ac.jp/amo/

Case Report

A Case of Focal Bone Marrow Reconversion Mimicking Bone Metastasis: The Value of ¹¹¹Indium Chloride

Takashi Tanaka^a*, Hideo Gobara^a, Ryota Inai^a, Toshihiro Iguchi^a, Akihiro Tada^a, Shuhei Sato^a, Hiroyuki Yanai^b, and Susumu Kanazawa^a

Departments of ^aRadiology and ^bPathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan

We present a case of a 66-year-old man with esophageal carcinoma. ¹⁸Fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) for evaluating distant metastasis and staging revealed ¹⁸F-FDG uptake in the third lumbar vertebra and other vertebrae. Magnetic resonance imaging could not differentiate bone metastases from benign bone lesions. We considered the possibility of bone marrow reconversion. ¹¹¹Indium chloride (¹¹¹In-Cl₃) scintigraphy with single-photon emission computed tomography/computed tomography (SPECT/CT) revealed erythroid bone marrow components in the bone lesions. The diagnosis of bone marrow reconversion was pathologically confirmed by a bone biopsy of the third lumbar vertebra. The patient underwent esophagectomy and has remained disease-free in the 2 years since. To the best of our knowledge, this is the first report to describe the usefulness of ¹¹¹In-Cl₃ with SPECT/CT for the diagnosis of bone marrow reconversion.

Key words: ¹¹¹Indium chloride scintigraphy, SPECT/CT, bone marrow reconversion, ¹⁸F-FDG PET/CT, bone metastasis

18 Fluorodeoxyglucose positron emission tomography/computed tomography (18 F-FDG PET/CT) has become an acceptable and established diagnostic tool for both cancer diagnosis and staging. Benign bone lesions such as bone marrow reconversion are sometimes confused with bone metastasis on 18 F-FDG PET/CT and magnetic resonance imaging (MRI) [1, 2]. We report a case of bone marrow reconversion that mimicked bone metastasis in a patient with esophageal carcinoma, and demonstrate that 111 Indium chloride (111 In-Cl₃) with single-photon emission computed tomography/CT can contribute to the diagnosis of bone marrow reconversion.

To the best of our knowledge, this is the first report to describe the usefulness of 111 In–Cl₃ with SPECT/CT for the diagnosis of bone marrow reconversion.

Case Report

A 66-year-old man (height 154 cm, body weight 62.9 kg) with a history of heavy smoking and alcoholinduced cirrhosis was referred to our hospital for treatment of esophageal squamous cell carcinoma. He had no clinical symptoms such as abdominal pain or lumbago. His blood pressure was 134/71 mmHg, pulse was 89 beats/min and oxygen saturation on room air

Received November 12, 2015; accepted March 14, 2016. *Corresponding author. Phone:+81-86-235-7313; Fax:+81-86-235-7316 E-mail:p9r543qa@s.okayama-u.ac.jp (T. Tanaka)

Conflict of Interest Disclosures: No potential conflict of interest relevant to this article was reported.

286 Tanaka et al.

was 99%. The results of his physical examination were normal. The results of laboratory examinations, including white blood cell count, platelet count, and levels of hemoglobin, C-reactive protein, alkaline phosphatase, and lactate dehydrogenase were within the normal ranges. Levels of tumor markers, including squamous cell carcinoma antigen and carcinoembryonic antigen, were within normal limits. The patient's serum carbohydrate antigen 19–9 level was slightly elevated (69.8 U/mL). Upper gastrointestinal endoscopy and biopsy showed two 35–mm type 0–IIc moderately differentiated squamous cell carcinoma lesions in the upper third of the esophagus.

A CT scan showed no obvious distant metastases but revealed slightly enlarged lymph nodes in the recurrent laryngeal nerve regions on both sides. ¹⁸F– FDG PET/CT for the evaluation of distant metastasis and staging showed accumulations of ¹⁸F–FDG in the main tumors and no significant accumulation of ¹⁸F– FDG in the mediastinal lymph nodes, but there was ¹⁸F–FDG uptake in the third lumbar (L3) vertebra (maximum standardized uptake value [SUVmax]: 4.12) and subtle uptake in the other vertebrae (arrowhead) (Fig. 1).




Fig. 1 ¹⁸Fluorodeoxyglucose positron emission tomography/ computed tomography (¹⁸F-FDG PET/CT) findings. A sagittal reconstructed ¹⁸F-FDG PET/CT image showing high uptake in the third lumbar (L3) vertebral body (arrow) and subtle uptake in the other vertebrae (arrowhead). The maximum standardized uptake value (SUVmax) of the L3 vertebra was 4.12.

On the CT images obtained by an integrated ¹⁸F-FDG PET/CT scanner, this uptake corresponded with a slightly high-attenuation bone lesion with preserved bone trabeculae (not shown). MRI of the spine showed a hyperintense bone lesion on short tau inversion recovery (STIR) images and a hypointense lesion on T1-and T2-weighted images of the L3 vertebra (Fig. 2, arrows). Fat-saturated T1-weighted images after gadolinium administration showed diffuse enhancement of the L3 vertebral lesion. Focal bone lesions with similar MR signal features were detected in the other lumbar vertebrae (Fig. 2, arrowheads). Normal fatty marrow was seen in the background of the spine. We considered the possibility of bone marrow reconversion of the L3 vertebra. For further evaluation, ¹¹¹In–Cl₃ scintigraphy with SPECT/CT was performed 48 h after intravenous injection of 74 MBg of ¹¹¹In-Cl₃ using a dual-head camera (GE Discovery NM/CT 670, GE Healthcare, Waukesha, WI, USA). Planar and SPECT/CT scintigraphy showed an abnormal increase in tracer uptake in the L3 vertebra (arrows) and subtle uptake in the other vertebrae (arrowhead) (Fig. 3). The ¹¹¹In–Cl₃ uptake pattern detected by SPECT/CT was similar to the ¹⁸F-FDG uptake pattern corresponding to the bone lesions on MRI. On the basis of these imaging features, bone marrow reconversion was strongly suspected. However, to confirm bone marrow reconversion, a CT-guided bone biopsy with a 13gauge bone biopsy needle was taken from the L3 vertebral lesion. Histological examination did not reveal any cancer cells, but did show hypercellular bone marrow (Fig. 4). The patient underwent esophagectomy. Histological examination from the resected specimen showed that moderately differentiated squamous cell carcinoma had invaded the submucosal layer (the middle third) with mild venous invasion, but detected no lymphatic invasion or lymph node metastasis. The patient has been regularly followed up and remains disease-free 2 years after surgery.

Discussion

At birth, hematopoietic (red) bone marrow is present throughout the entire skeleton, but then starts to convert to fatty (yellow) bone marrow [3]. This maturation process typically progresses from the peripheral to the central skeleton and is usually completed by the age of 25 years, although its speed depends on




Fig. 2 Magnetic resonance imaging (MRI) findings. Sagittal T1-weighted (A) and T2-weighted (B) spin-echo MR images of the thoracolumbar spine showing a focal hypointense lesion in the L3 vertebral body (arrows). Sagittal short tau inversion recovery (STIR) image (C) and fat-saturated T1-weighted image after gadolinium administration (D) showing a hyperintense lesion with contrast enhancement in the L3 vertebral body (arrows). Patchy focal bone lesions with similar signal features to the L3 bone lesion were detected in the other lumbar vertebrae (arrowheads).




Fig. 3 111 Indium chloride (111 In–Cl₃) scintigraphy with single-photon emission computed tomography/computed tomography (SPECT/CT) findings. The posterior planar (A) and SPECT/CT (B coronal) scintigraphy images showing abnormal increase in tracer uptake in the L3 vertebra (arrows) and subtle uptake in the other vertebrae (arrowhead). The 111 In–Cl₃ uptake pattern detected by SPECT/CT was similar to the 16 F–FDG uptake pattern corresponding to the bone lesions on MRI.

288 Tanaka et al.




Fig. 4 Pathological findings. Bone biopsy specimen of the L3 vertebral lesion showed hypercellular bone marrow with a reduced proportion of adipocytes. No neoplastic cells were seen (hematox-ylin and eosin staining).

an individual's sex and underlying medical conditions. Red marrow consists of 40% water, 40% fat, and 20% protein, whereas yellow marrow consists of 15% water, 80% fat, and 5% protein [4]. In normal adult marrow, yellow marrow may reconvert to the marrow under conditions that cause a need for increased hematopoiesis. This reconversion may have several causes, including stress, obesity, middle age (in women), heavy smoking, long-distance running, high-altitude living, obstructive sleep apnea syndrome, chronic anemia, and administration of hematopoietic growth factors [3, 4]. The reconversion process proceeds in the reverse pattern of the original red-to-yellow conversion. It may occur diffusely, or focal areas of the red marrow may appear in a background of the yellow marrow [2, 3]. In our patient, a smoking history may have contributed to the progression of bone marrow reconversion.

Several imaging modalities, such as bone scintigraphy, CT, MRI, and ¹⁸F–FDG PET/CT, are used to evaluate bone lesions. Currently, MRI and ¹⁸F–FDG PET/CT have been playing important roles in the detection and evaluation of bone metastases. However, bone marrow reconversion is sometimes misdiagnosed as bone metastasis because of its high cellularity, although in some cases non-neoplastic bone lesions can be easily differentiated from neoplastic lesions on MR images such as in-phase and out-of-phase gradient-echo MR imaging [5]. Reconverted bone marrow may show a masslike pattern with high cellularity and MR signal characteristics of hypercellular hematopoietic marrow, and those of tumor infiltration or highly cellular neoplastic bone marrow can be similar [2, 6]. Like MRI, ¹⁸F-FDG PET/CT may give false-positive results for bone metastasis [1]. A previous report evaluating imaging features of hyperplastic hematopoietic bone marrow and bone metastasis showed that if the SUVmax of a bone lesion was more than 3.6 on ¹⁸F-FDG PET/CT, the lesion could be considered metastatic [7]. In our case, the multiple bone lesions detected on ¹⁸F-FDG PET/CT and MRI were similar to tumor infiltrations caused by bone metastases, and we could not rule out the possibility of malignancy.

¹¹¹In-Cl₃ scintigraphy with SPECT/CT could be an additional diagnostic tool for focal bone marrow reconversion. ¹¹¹In-Cl₃ scintigraphy is a noninvasive method for evaluating the anatomic extent of the erythropoietic element. Iron radionuclides are ideal physiologically but are unsuitable for erythroid bone marrow scintigraphy because of their high-energy radiation. ¹¹¹In-Cl₃ has been used clinically as a reliable alternative tracer in bone marrow scintigraphy because of its transportation in the plasma by transferrin and its suitable energy characteristics [8]. After intravenous injection, ¹¹¹In–Cl₃ is rapidly coupled to serum transferrin and eliminated from the plasma with a half-life of 5h. Approximately 30% of the administered tracer is found in the bone marrow, 20% in the liver, 7% in the kidneys, and 1% in the spleen. The remaining activity is distributed throughout the body fluids without any specific tissue accumulation [9]. In previous reports, planar scintigraphy with ¹¹¹In–Cl₃ was usually used to predict the clinical severity of diffuse bone marrow diseases such as myelofibrosis, aplastic anemia, and myelodysplastic syndrome, particularly to detect the disappearance of a physiologically active bone marrow [8-10]. Planar scintigraphy alone is not sufficient to evaluate and diagnose focal bone lesions. A new hybrid imaging system, SPECT/CT, has advantages over planar imaging because it provides a more precise localization of lesions with focal tracer uptake and improves clinical diagnostic confidence. In our case, ¹¹¹In-Cl₃ accumulation detected by SPECT/CT conformed remarkably to the images of FDG-PET/CT and MRI, thus contributing to the correct diagnosis.

We encountered a case of bone marrow reconversion that mimicked bone metastasis in a patient with

August 2016

esophageal carcinoma. The bone marrow reconversion was ultimately diagnosed using a biopsy specimen. $^{111}In\text{-}Cl_3$ scintigraphy with SPECT/CT can contribute to the diagnosis of bone marrow reconversion.

References

- Ida S, Watanabe M, Yamao T, Ishimoto T, Nagai Y, Iwatsuki M, Baba Y, Iwagami S, Sakamoto Y, Miyamoto Y and Baba H: False-positive 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) findings of bone metastasis from esophagogastric cancer: report of two cases. Surg Today (2014) 44: 2191–2194.
- Bordalo-Rodrigues M, Galant C, Lonneux M, Clause D and Vande Berg BC: Focal nodular hyperplasia of the hematopoietic marrow simulating vertebral metastasis on FDG positron emission tomography. AJR Am J Roentgenol (2003) 180: 669–671.
- Hwang S and Panicek DM: Magnetic resonance imaging of bone marrow in oncology, Part 1. Skeletal Radiol (2007) 36: 913–920.
- Malkiewicz A and Dziedzic M: Bone marrow reconversion-imaging of physiological changes in bone marrow. Pol J Radiol (2012)

A Case of Focal Bone Marrow Reconversion 289

77: 45-50.

- Disler DG, McCauley TR, Ratner LM, Kesack CD and Cooper JA: In-phase and out-of-phase MR imaging of bone marrow: prediction of neoplasia based on the detection of coexistent fat and water. AJR Am J Roentgenol (1997) 169: 1439–1447.
- Hwang S and Panicek DM: Magnetic resonance imaging of bone marrow in oncology, Part 2. Skeletal Radiol (2007) 36: 1017–1027.
- Shigematsu Y, Hirai T, Kawanaka K, Shiraishi S, Yoshida M, Kitajima M, Uetani H, Azuma M, Iryo Y and Yamashita Y: Distinguishing imaging features between spinal hyperplastic hematopoietic bone marrow and bone metastasis. AJNR Am J Neuroradiol (2014) 35: 2013–2020.
- McNeil BJ, Rappeport JM and Nathan DG: Indium chloride scintigraphy: an index of severity in patients with aplastic anaemia. Br J Haematol (1976) 34: 599–604.
- Agool A, Glaudemans AW, Boersma HH, Dierckx RA, Vellenga E and Slart RH: Radionuclide imaging of bone marrow disorders. Eur J Nucl Med Mol Imaging (2011) 38: 166–178.
- Nakai T, Okuyama C, Kubota T, Kobayashi K, Tsubokura T, Ushijima Y and Nishimura T: Pattern of 111In-chloride bone marrow scintigraphy in myelodysplastic syndrome: comparison with clinical characteristics. Ann Nucl Med (2004) 18: 675–680.